ArticleJournal of translational medicine2018
Symptomatic anterior cruciate ligament tears treated with percutaneous injection of autologous bone marrow concentrate and platelet products: a non-controlled registry study.
Article in Journal of translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03011398 (Interventional Orthopedics Foundation Patient Registry Database-A Clinical Registry of Orthobiologics Procedures), which is not on this map. Cited by 16 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Interventional Orthopedics Foundation Patient Registry Database-A Clinical Registry of Orthobiologics Procedures
Who cites it
16 citing papers in PubMed, 4 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Autologous platelet concentrate augmentation in anterior cruciate ligament reconstruction: a level I evidence-based meta-analysis.Orthopadie (Heidelberg, Germany) · 2026Pooled it
- The effect of platelet-rich plasma on clinical outcomes within two years after anterior cruciate ligament reconstruction: a systematic review and meta-analysis of randomized controlled trials.Journal of orthopaedic surgery and research · 2025Pooled it
- Biological augmentation of anterior cruciate ligament reconstruction with bone marrow aspirate concentrate: a systematic review and meta-analysis of randomised controlled trials.International orthopaedics · 2025Pooled it
- Mesenchymal Stem Cells for Treatment of Tendon and Ligament Injuries-clinical Evidence.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2020Pooled it
- Non-surgical treatment of anterior cruciate ligament tears with percutaneous bone marrow concentrate and platelet products versus exercise therapy: a randomized-controlled, crossover trial with 2-year follow-up.BMC musculoskeletal disorders · 2025Trial
- Effect of bone marrow aspiration concentrate and platelet-rich plasma combination in anterior cruciate ligament reconstruction: a randomized, prospective, double-blinded study.Journal of orthopaedic surgery and research · 2024Trial
- Orthobiologics in anterior cruciate ligament injuries.Journal of experimental orthopaedics · 2026Review
- A clinical practice review: augmentation of meniscoligamentous structures for primary prevention of knee joint deterioration.Annals of joint · 2026Review
- Primary repair of proximal anterior cruciate ligament injury: a global expert consensus statement.Burns & trauma · 2025Article
- Nanosurgical and Bioengineering Treatment of Human Anterior Cruciate Ligament Tears with Ultrasound-Guided Injection of Modified Platelet-Rich Plasma Using Human Cell Memory Based on Clinical, Ultrasound, MRI, and Nanoscope Analyses: A Double-Blind Randomized Trial.Journal of clinical medicine · 2024Article
- Evaluating the Use of PROMs in Paediatric Orthopaedic Registries.Children (Basel, Switzerland) · 2023Review
- Targeted Nanoparticles with High Heating Efficiency for the Treatment of Endometriosis with Systemically Delivered Magnetic Hyperthermia.Small (Weinheim an der Bergstrasse, Germany) · 2022Article
- Cell-based treatment options facilitate regeneration of cartilage, ligaments and meniscus in demanding conditions of the knee by a whole joint approach.Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2022Review
- Platelet-rich plasmaWorld journal of stem cells · 2021Review
- Application of Stem Cell Therapy for ACL Graft Regeneration.Stem cells international · 2021Review
- Stem Cell Treatment for Ligament Repair and Reconstruction.Current reviews in musculoskeletal medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBone marrow concentrate (BMC) has shown promise in the treatment of several orthopedic conditions. This registry study investigated the use of autologous BMC and platelet products for percutaneous anterior cruciate ligament (ACL) treatment.
methodsTwenty-nine patients presenting to a single outpatient interventional musculoskeletal and pain practice with symptomatic grade 1, 2, or 3 ACL tears with less than 1 cm retraction were enrolled. Patients were treated with a percutaneous ACL injection of autologous BMC and platelet products using fluoroscopic guidance. Pre- and post-treatment magnetic resonance imaging analysis was completed for 23 patients using ImageJ software for an objective quantitative analysis of pixel density as a proxy for ACL integrity. Subjective clinical outcome measures collected pre-treatment and at 1, 3, 6, 12, 18, 24, and 36 months post-treatment include the Numerical Pain Scale (NPS), the Lower Extremity Functional Scale (LEFS), the International Knee Documentation Committee (IKDC) form, and a modified version of the Single Assessment Numeric Evaluation.
resultsSeventy-seven percent of patients treated with BMC injections into the ACL showed significant improvement (p < 0.01) in objective measures of ACL integrity at an average of 8.8 months (median 4.7 months). The mean of last patient-reported improvement was 72% (SD = 35) at an average of 23 (SD = 10) months post-treatment. Mean scores were found to be significantly different (p < 0.05) for the NPS at 6, 18, and 24 months, and LEFS and IKDC at all time points (i.e. 1, 3, 6, 12, 18, 24, and 36 months) relative to baseline.
conclusionIn symptomatic patients with grade 1, 2, or even grade 3 tears with minimal retraction, ACL treatment with percutaneous injection of BMC and platelet products shows promise as a non-surgical alternative. However, a larger randomized controlled trial is warranted to confirm these findings. Trial registration NCT03011398. A Clinical Registry of Orthobiologics Procedures. https://clinicaltrials.gov/ct2/show/NCT03011398?term=orthobiologics&rank=1 . Registered 29 December 2016. Enrollment 1 December 2011-retrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.